Inhibikase Therapeutics: director Scott M. Wasserman received 310,000 shares

What happened

• The filing reports that Scott M. Wasserman, a director, received a grant of 310,000 derivative securities on Oct 19, 2026, at an acquisition price of $0.00, total $0. The Form 4 was filed Oct 21, 2026.

Key details

• Transaction date and price: Oct 19, 2026 — grant of 310,000 shares at $0.00 (transaction code A).
• Shares owned after the transaction: not reported in this filing.
• Footnote: the grant will vest and become exercisable in equal annual installments over 3 years commencing Oct 19, 2026, subject to the reporting person's continued service through each vesting date (footnote F1).
• Filing date: Oct 21, 2026.

Why it may matter

• The filing reports a grant of derivative securities (an option award) with a 3-year vesting schedule; it is not a sale or a market trade. A filing does not show why the insider traded or why the company acted.